Recent Quotes (30 days)

You have no recent quotes
chg | %

Cascadian Therapeutics Inc (USA)  

(Public, NASDAQ:CASC)   Watch this stock  
Find more results for Nasdaq:ONTY
-0.06 (-1.50%)
Real-time:   3:35PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.94 - 4.09
52 week 3.18 - 10.98
Open 4.04
Vol / Avg. 175,252.00/330,318.00
Mkt cap 199.69M
P/E     -
Div/yield     -
EPS -1.58
Shares 50.55M
Beta 2.28
Inst. own 84%
Sep 27, 2017
Cascadian Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference - 9:45AM EDT - Add to calendar
Aug 8, 2017
Q2 2017 Cascadian Therapeutics Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -38.98% -64.17%
Return on average equity -40.74% -76.28%
Employees 57 -
CDP Score - -


2601 4th Ave Ste 500
SEATTLE, WA 98121-3222
United States - Map
+1-206-8012100 (Phone)
+1-206-8012101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company's ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.

Officers and directors

Christopher S. Henney Ph.D. Chairman of the Board
Age: 76
Bio & Compensation  - Reuters
Scott D. Myers President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Julia Marie Eastland Chief Financial Officer, Vice President - Corporate Development, Secretary
Age: 51
Bio & Compensation  - Reuters
Gary W. Christianson Chief Operating Officer
Age: 61
Bio & Compensation  - Reuters
Scott Peterson Ph.D. Chief Scientific Officer
Age: 54
Bio & Compensation  - Reuters
Robert W. Azelby Director
Age: 49
Bio & Compensation  - Reuters
Gwendolyn A. Fyfe M.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
Steven P. James Independent Director
Age: 57
Bio & Compensation  - Reuters
Ted W. Love M.D. Independent Director
Age: 58
Bio & Compensation  - Reuters
Daniel Keith Spiegelman Independent Director
Age: 58
Bio & Compensation  - Reuters